CVS - CVS Health Corporation
| Previous close | 68.03 |
| Open | 68.34 |
| Bid | 69.62 x 900 |
| Ask | 69.63 x 1000 |
| Day's range | 68.05 - 69.69 |
| 52-week range | 66.34 - 107.26 |
| Volume | |
| Avg. volume | 8,546,553 |
| Market cap | 89.281B |
| Beta (5Y monthly) | 0.60 |
| PE ratio (TTM) | 23.14 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.42 (3.60%) |
| Ex-dividend date | 20 Apr 2023 |
| 1y target est | N/A |
- Motley Fool
3 Reliable Dividend Growth Stocks to Buy Hand Over Fist in June
Adding these well-respected dividend payers to your portfolio could give you a stream of passive income that grows throughout your retirement years.
- Motley Fool
The Top Healthcare Stocks to Buy With $100
The healthcare industry is diverse and complex, with longtime staples and emerging disruptors to fit your portfolio -- and it also doesn't need to cost an arm and a leg. Here are several possibilities to consider, each playing a different role in the healthcare system. In an industry where size matters, Pfizer (NYSE: PFE) is one of the industry's most prominent players, with a market cap of over $200 billion.
- Zacks
Here's Why You Should Retain CVS Health (CVS) Stock for Now
Investors are optimistic about CVS Health (CVS) on continued growth across the entire range of insured and self-insured medical, pharmacy, dental and behavioral health products and services.
- Zacks
Investors Heavily Search CVS Health Corporation (CVS): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.
- Zacks
The Zacks Analyst Blog Highlights Alphabet, Raytheon, Blackstone, SAP SE and CVS Health
Alphabet, Raytheon, Blackstone, SAP SE and CVS Health are included in this Analyst Blog.
- Zacks
Top Analyst Reports for Alphabet, Raytheon Technologies & Blackstone
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Raytheon Technologies Corporation (RTX) and Blackstone Inc. (BX).
- Motley Fool
After Announcing Cuts, Is CVS Still a Safe Stock?
On Sunday, CVS Health (NYSE: CVS) revealed that it would be shuttering its clinical trial services segment by the end of 2024, according to reporting from biopharma industry trade publication Endpoints News. The pharmacy and health insurance giant began its foray into this space in 2021, and originally used its access to consumers to aid drugmakers in recruiting participants for COVID-19 vaccine trials and other coronavirus-related clinical investigations, but apparently, management doesn't feel that the business is contributing significantly to the company's prospects. Does this mean that CVS stock isn't as safe as shareholders have believed?
- Motley Fool
Can Walgreens Succeed in This Market Where CVS Failed?
When CVS Health (NYSE: CVS) said on May 14 that it would exit its clinical trial services business after just two years in operation, management at Walgreens Boots Alliance (NASDAQ: WBA) was quick to confirm that it would still be moving forward full speed with building out its own service. Now, the smaller pharmacy chain will have the benefit of one less major competitor trying to work with drug developers to build out their clinical trials. Why bother to get into clinical trials in the first place?
- Zacks
Insider Watch: 2 CEOs Buying Shares
Insiders have a longer-term holding horizon than most, a critical aspect that market participants should know. Nonetheless, seeing an insider step in and buy is always reassuring.
- Yahoo Finance Video
Chipotle 'pivoted just the right way' into digital during the pandemic: Analyst
Laffer Tengler Investments CEO and CIO Nancy Tengler joins Yahoo Finance Live to discuss stocks to buy, including Starbucks, Chipotle, and Tesla, and stocks to avoid, including Disney and CVS.
- Motley Fool
3 Exceptional Dividend Stocks That Retirees Should Love
All of these stocks offer reliable dividend payments that could help make your retirement dreams a reality.
- Yahoo Finance
Walgreens sees benefit from CVS exiting clinical trial business
Walgreens remains bullish on its clinical trials segment as rival CVS announces closure.
- Motley Fool
1 Deeply Undervalued Dividend Stock to Buy in May
Many of the greatest investors of all time could be considered value investors. One stock that seems to be greatly undervalued right now is pharmacy chain and health insurer CVS Health (NYSE: CVS). Let's take a peek under the hood at its fundamentals and valuation to better understand why the stock could be a no-brainer buy for value investors this month and beyond.
- Yahoo Finance
Why indie pharmacies, with the help of the likes of Mark Cuban, are on the rise
Independent pharmacies and startups such as Cigna's Express Scripts and Mark Cuban's Cost Plus Drugs are partnering up to address a coverage gap for some Americans.
- Zacks
CVS Health Corporation (CVS) is Attracting Investor Attention: Here is What You Should Know
CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- Motley Fool
Walmart Is Diving Deeper Into Healthcare: What Does That Mean for Pharmacies?
Walmart (NYSE: WMT) is a large, well-funded, low-cost competitor that no company wants to go up against if they can avoid it. For big pharmacy retailers such as Walgreens Boots Alliance (NASDAQ: WBA) and CVS Health (NYSE: CVS), may soon find out what it feels like (even more than they already do). Walmart is a dominant name in retail as its low-priced merchandise draws in many consumers looking to save money, particularly now amid outsized and persistent inflation.
- Motley Fool
Myth Buster: Customer Donations Do Not Reduce Corporate Taxes
There's a story going around that retailers use customer donations to charity to line their own pockets. Keep reading to learn why that's not true.
- Motley Fool
CVS Health Is a Screaming Buy on the Dip
Shares of the healthcare giant are down more than 30% over the past six months, despite steadily growing profits from a rapidly growing collection of indispensable businesses.
- Motley Fool
2 High-Yielding Dividend Stocks Analysts Expect Will Rise by at Least 50%
Investors often gloss over dividend stocks, assuming that they offer nothing more than a recurring payout. CVS Health is a top healthcare business that pays an attractive dividend yield of 3.3%. On a $25,000 investment, that would generate about $825 in dividend income over the course of a full year.
- Yahoo Finance Video
CVS stock dips after cutting its 2023 forecast
The Yahoo Finance Live team discusses a drop in CVS stock after the company cuts its forecast for the year.
- Motley Fool
CVS Health (CVS) Q1 2023 Earnings Call Transcript
Image source: The Motley Fool. CVS Health (NYSE: CVS)Q1 2023 Earnings CallMay 03, 2023, 10:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorLadies and gentlemen, good morning, and welcome to the CVS Health first quarter 2023 earnings conference call.
- Zacks
CVS Health (CVS) Q1 Earnings Surpass Estimates, EPS View Cut
CVS Health's (CVS) robust sales growth across all three operating segments drives top-line results.
- Zacks
CVS Health (CVS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for CVS Health (CVS) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- Yahoo Finance Video
CVS stock slips despite Q1 earnings beat
Yahoo Finance’s Anjalee Khemlani joins the Live show to break down the decline in stock for CVS following first-quarter earnings and discuss the leading health solutions company’s recent acquisitions.
- Zacks
Is CVS Health (CVS) a Buy as Wall Street Analysts Look Optimistic?
Based on the average brokerage recommendation (ABR), CVS Health (CVS) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
